---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-361895"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-08-24T12:15:14+00:00"
generated_at: "2026-08-24T12:20:06.336881+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca gets FDA Fast Track for ERAS-0015 in metastatic pancreatic cancer

## Summary
- FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma on Aug 24, 2026.
- FTD may enable accelerated approval, priority review, and rolling review if criteria met.
- Company plans phase 3 trial in pancreatic cancer and two registration-enabling trials in lung cancer.
- FTD does not change approval standards; FDA may later revoke designation or not shorten review.

## SEC filing metadata
- accession: 0001193125-26-361895
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-08-24T12:15:14+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/0001193125-26-361895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/eras-20260824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-361895
- JSON: https://secwatch.observer/filing/0001193125-26-361895.json
- Plain text: https://secwatch.observer/filing/0001193125-26-361895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.